Spyre Therapeutics Inc. (SYRE)
NASDAQ: SYRE
· Real-Time Price · USD
16.92
-0.03 (-0.18%)
At close: Aug 18, 2025, 3:59 PM
17.25
1.95%
After-hours: Aug 18, 2025, 05:28 PM EDT
-0.18% (1D)
| Bid | 16.21 |
| Market Cap | 1.02B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -206.81M |
| EPS (ttm) | -2.53 |
| PE Ratio (ttm) | -6.69 |
| Forward PE | -4.56 |
| Analyst | Buy |
| Ask | 17.9 |
| Volume | 328,689 |
| Avg. Volume (20D) | 539,908 |
| Open | 16.95 |
| Previous Close | 16.95 |
| Day's Range | 16.69 - 17.40 |
| 52-Week Range | 10.91 - 40.26 |
| Beta | 2.83 |
About SYRE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SYRE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SYRE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-11.64%
SYRE stock has given up its prior gain. Spyre Ther...
Unlock content with
Pro Subscription
2 months ago
-11.64%
Spyre Therapeutics shares are trading higher after the company announced interim Phase 1 results from its first-in-human trials of SPY002 and SPY072.
2 months ago · seekingalpha.com
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways ForwardSpyre Therapeutics, Inc.'s SPY002 and SPY072 drug candidates showed strong safety and TL1A inhibition in a phase 1 study, supporting advancement to phase 2 clinical development. SPY002 targets ulcerat...
